Last Updated on January 6, 2023 by The Health Master
Mumbai: Scientists from Mumbai’s Tata Institute of Fundamental Research (TIFR), the Agharkar Research Institute (ARI) in Pune, and IIT Hyderabad have discovered an alternative drug molecule indicating high antitumor potential on cancer cells with exceptional ability to reduce unwanted growth of blood vessels (antiangiogenic effect), said one of the scientific team members.
This advancement is significant given the limited applicability of platinum drugs, which are currently the main treatment option for many types of cancer due to patient resistance.
The study was jointly conducted by a team comprising TIFR’s Malay Patra, Manikandan M., Sushanta Chhatar, Shubhankar Gadre, ARI’s Chinmay Patra and Gourav Chakraborty, and IIT-Hyderabad’s Naushad Ahmed.
Malay Patra said that the new therapeutic agent, ‘Ruthenium-Ferrocene Bimetallic’, has the potential to curb primary tumour growth through antiproliferation (use for inhibiting cell growth) and check metastasis (growth) through antiangiogenesis, or “killing two birds with one stone.”
Patra, who is the Principal Investigator, Medicinal Chemistry and Cell Biology Laboratory at the TIFR’s Department of Chemical Sciences, said that the new agent restricts new blood vessel development and can help treat cancer cases that prove resistant to platinum drugs used to treat the disease.
So far, he said, extensive biological investigations have been undertaken in cellular models and on zebrafish, and the team is now planning to experiment with the anti-cancer properties and toxicity of the new agent in mammals like mice.
The team’s research has been published in the ACS journal, showing the potential therapeutic implications of the therapeutic agents to manage platinum-resistant cancers, Patra said.
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon: